Track market-moving stories before they get noisy

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. 

We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of NIKE, Inc. (NYSE: NKE) breached their fiduciary duties to shareholders.

If you currently own NIKE stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Key Takeaways NIKE sees early footwear stabilization with gains in running, basketball and global football.Newer performance franchises are expanding as NIKE reduces reliance on older classic styles.Inventory-clearing, discounting and competition persist, but sell-through trends are improving. NIKE Inc. (NKE - Free Report) is showing early signs of stabilization in its core footwear business following several quarters marked by inventory imbalances, elevated promotional activity and evolving consumer preferences. As the largest contributor to the company’s revenue base, footwear remains central to NIKE’s turnaround efforts. Recent management commentary suggests that the company is making progress in restoring marketplace health, improving product assortments and strengthening demand across key performance categories.

A notable sign of stabilization is the improving traction in strategic footwear segments such as running, basketball and global football. Management highlighted strong momentum in running and double-digit growth in football, reflecting positive consumer response to newer product offerings. At the same time, NIKE is intentionally reducing its dependence on older classic franchises and reallocating resources toward innovation-led platforms that can drive sustainable growth. This portfolio shift is aimed at improving product productivity while enhancing the overall quality of sales.

While encouraging signs are emerging, the recovery is far from complete. Footwear performance remains constrained by inventory-clearing efforts, elevated discounting and intense competition across key markets. Nevertheless, improving sell-through trends, stronger wholesale engagement and a more focused innovation pipeline indicate that the business may be moving toward a healthier footing. If NIKE can successfully balance inventory discipline with new product launches, its footwear segment could become a key catalyst for broader revenue and earnings stabilization.

Management’s focus on expanding newer performance franchises while reducing reliance on legacy styles should also support a healthier product mix. If these initiatives continue to gain traction, the footwear business could emerge from the current transition period with stronger growth and profitability prospects.

NKE’s Competition in the Global Arenaadidas AG (ADDYY - Free Report) and lululemon athletica inc. (LULU - Free Report) are NKE’s key competitors in the global market.

adidas is seeing encouraging signs of stability in its footwear business as strong demand for running, football and Originals continues to support growth across key markets. Management has emphasized product visibility, franchise strength and disciplined inventory management as drivers of healthier marketplace dynamics. Improved full-price sell-through and sustained consumer interest in both performance and lifestyle offerings suggest that adidas’ footwear segment is benefiting from stronger brand momentum and a more balanced product portfolio.

lululemon is steadily strengthening its footwear business through innovation and expansion across targeted categories. While footwear remains a smaller contributor compared with apparel, the company continues to broaden its product assortment and deepen consumer engagement through a premium, performance-focused approach. Supported by its loyal customer base, direct-to-consumer model and growing brand awareness, lululemon is positioning footwear as an important long-term growth opportunity while maintaining disciplined inventory and pricing strategies.

NKE’s Price Performance, Valuation & EstimatesShares of NIKE have lost 24% in the past three months compared with the industry’s decline of 18.9%.

Image Source: Zacks Investment Research

From a valuation standpoint, NKE trades at a forward 12-month price-to-earnings ratio of 23.03X compared with the industry’s average of 20.22X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for NKE’s fiscal 2026 earnings implies a year-over-year decline of 31%, while that for fiscal 2027 indicates growth of 24.3%. The company’s EPS estimates for fiscal 2026 and 2027 have been stable in the past 30 days.
 

Image Source: Zacks Investment Research

It is World Cup time, as the month-long soccer tournament kicks off June 11 throughout North America and lasts until July 19.

Perhaps no U.S. brand is tied to the "beautiful game" more than Nike (NKE 2.24%). While Nike is not an official sponsor of the FIFA World Cup, many of the sport's leading players, like Cristiano Ronaldo and Kylian Mbappé, have endorsement deals with Nike. Also, Nike provides the shoes and "kits" for 12 teams, including France, England, Brazil, the United States, Canada, and the Netherlands.

So, Nike will have a ton of visibility over the next month, not just from the players on the field, but on the airwaves and in social media through an advertising campaign it is launching for the World Cup.

Image source: Getty Images.

Rip the Script Rip the Script is Nike's new World Cup ad campaign, highlighted by a star-studded 6-minute film. It's designed to introduce the universe of Nike football -- the game, the players, the culture, and, of course, Nike shoes and apparel.

"We are also utilizing the World Cup as an opportunity to catalyze the football marketplace for quarters to come," CEO Elliott Hill said on the fiscal Q3 earnings call. "By the end of the tournament, we will have elevated our presentation in more than 5,000 football doors around the world, with wholesale partners and Nike Direct." 

One of the major changes that Hill has ushered in since becoming CEO is renewing the focus on wholesale channels, like Dick's Sporting Goods, Foot Locker, Shoe Palace, and Academy Sports. Wholesale sales were up 5% in the last quarter, while direct sales were down 5% and overall sales were flat.

Hill said he expects to deepen the relationship with these wholesalers through the World Cup.

While Nike has some wholesale sales momentum, it is saddled with declining earnings. In the latest quarter, the third quarter of fiscal year 2026, which ended Feb. 28, expenses rose 2%, and cost of sales jumped 2% due in large part to tariffs. The higher tariffs have contributed to the 3% decline in gross profits and a 130-basis-point drop in gross margin to 40.2%. As a result, net income plummeted 35%.

CFO Matthew Friend said on the call that tariffs will be a headwind until Q2 of fiscal 2027, when mitigation efforts kick in. But the outlook is for a low-single-digit revenue decline through calendar year 2026, and continued margin pressure. By Q2 2027, the December quarter, Friend said the company anticipates margin expansion and the beginning of an earnings recovery.

Today's Change

(

-2.24

%) $

-1.03

Current Price

$

44.93

So is Nike a buy now, given the World Cup's visibility around the corner? The tournament may not have much immediate impact on sales, but the visibility could give the stock a lift, as could a solid Nike Q4 earnings release on June 30.

With shares down 31% year to date, the stock is trading at 22 times earnings, down considerably from earlier levels.

I think Nike stock may actually be nearing the buy zone.

Here's why: Investors have already baked in depressed near-term sales and margins, so a decent earnings report, an expected earnings recovery in fiscal 2027, the visibility of the World Cup, and a reasonable valuation might just make Nike a buy heading into the World Cup.

RBC Capital Markets downgrades Nike stock to Sector Perform from Outperform and lowers its price target to $50 from $70 in a research note.

Stock futures slipped Wednesday morning as investors weighed renewed geopolitical tensions and fresh inflation data. Dow futures are off by triple digits, while S&P 500 and Nasdaq-100 futures are also pointed firmly lower, after President Donald Trump warned Iran that negotiations were taking “too long” and hinted at further action. Oil prices moved up 2% in response. Meanwhile, May’s core consumer price index rose 0.2% month over month, below economists’ 0.3% forecast, while the annual rate held steady at 2.9%, helping futures recover from earlier lows.

Continue reading for more on today's market, including:

This 2% SPX selloff may be different according to Senior Quantitative Analyst Rocky White. Historical pullback signaling Vertiv stock upside. Plus, SMCI sinks on stock sale, retailer jumping off Q3 report, and Nike continues spiraling. 

5 Things You Need to Know Today The Cboe Options Exchange saw more than 9.3 million call contracts and 9 million put contracts traded on Tuesday. The single-session equity put/call ratio fell to 0.96, while the 21-day moving average rose to 0.59.  Super Micro Computer (NASDAQ:SMCI) shares are down 12% premarket, after the tech hardware company announced it plans to raise $7 billion in stock-related deals to help cover hardware costs. SMCI stock is continuing the downtrend that began after a rejection at $50 earlier this month. Year-to-date, the stock is up 38% heading into today. Beloved country-themed restaurant chain Cracker Barrel (NYSE:CBRL) gained 11% before the bell after scoring a bottom-line beat for its fiscal third quarter, hiking its full-year revenue, and adjusting EBITDA guidance. CBRL is poised to open at a multi-month high.  Nike (NYSE:NKE) is down 2% ahead of today's open, reeling from a RBC downgrade to "sector perform" from "outperform," with notes of Nike's weak turnaround. Heading into today, Nike stock is still near eight-year lows and carries a 30% nine-month deficit. investors will be eyeing key financial reports later this week. 

Semiconductor Slide Hits Asia Asian markets moved lower on Wednesday as semiconductor stocks resumed their slide. The South Korean Kospi staged another big swing with a 4.5% loss, while Japan’s Nikkei dipped 1.9%, Hong Kong’s Hang Seng shed 0.6%, and China’s Shanghai Composite lost 0.4%.

European markets are broadly in the red as well. London’s FTSE 100 was last seen down 0.6%, while the French CAC 40 and German DAX drop 0.7% and 1.1%, respectively. Meanwhile, the DIW economic institute said Germany was likely to slip into a technical recession this year due to the war in Iran.

As the World Cup kicks off, Nike and Adidas are ​competing on and off the field.

Nike (NKE - Free Report) closed at $44.93 in the latest trading session, marking a -2.24% move from the prior day. This move lagged the S&P 500's daily gain of 0.5%. Elsewhere, the Dow saw an upswing of 0.7%, while the tech-heavy Nasdaq appreciated by 0.31%.

Shares of the athletic apparel maker have appreciated by 9.38% over the course of the past month, outperforming the Consumer Discretionary sector's gain of 1.82%, and the S&P 500's loss of 0.23%.

The upcoming earnings release of Nike will be of great interest to investors. The company's earnings report is expected on June 30, 2026. The company's upcoming EPS is projected at $0.11, signifying a 21.43% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.87 billion, down 2.03% from the year-ago period.

NKE's full-year Zacks Consensus Estimates are calling for earnings of $1.49 per share and revenue of $46.36 billion. These results would represent year-over-year changes of -31.02% and +0.11%, respectively.

Investors should also take note of any recent adjustments to analyst estimates for Nike. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 1.67% fall in the Zacks Consensus EPS estimate. Nike presently features a Zacks Rank of #4 (Sell).

Looking at valuation, Nike is presently trading at a Forward P/E ratio of 24.83. This signifies a premium in comparison to the average Forward P/E of 16.01 for its industry.

We can also see that NKE currently has a PEG ratio of 1.99. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. NKE's industry had an average PEG ratio of 1.93 as of yesterday's close.

The Shoes and Retail Apparel industry is part of the Consumer Discretionary sector. At present, this industry carries a Zacks Industry Rank of 94, placing it within the top 39% of over 250 industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Key Takeaways ACB shares are down 19% YTD, underperforming the cannabis industry's 15% decline.Aurora Cannabis is leaning on medical cannabis, with revenues up ~20% to C$211.5M in nine months.Aurora Cannabis is scaling back consumer cannabis amid pricing pressure and intensifying competition. Shares of Aurora Cannabis (ACB - Free Report) have lost 19% year to date compared with the industry‘s 15% decline, as shown in the chart below.

Image Source: Zacks Investment Research

The underperformance reflects a mix of sector-wide pressures and company-specific positioning. While intensifying competition in Canada’s mature cannabis market continues to weigh on Aurora Cannabis’ growth prospects, its limited presence in the United States has also constrained its ability to capitalize on recent cannabis-related policy momentum.

Let’s delve into the company’s fundamentals to better assess the stock following the decline.

Medical Cannabis Remains Aurora Cannabis’ Core Growth EngineAurora Cannabis continues to anchor its growth strategy around global medical cannabis, which remains the primary driver of both revenue and profitability. The segment has delivered consistent momentum, supported by strong demand across key international markets and a disciplined focus on higher-margin products.

For the nine months of fiscal 2026 (year ended March 2026), medical cannabis revenues increased about 20% year over year to C$211.5 million, accounting for nearly 75% of total sales. Growth was driven by increasing contributions from international markets, such as Germany, Australia and Poland, alongside steady demand in Canada from both insurance-covered and self-paying patients.

The strength of this segment is also evident in its margin profile. Higher-margin international sales, favorable product mix and ongoing production efficiencies have supported margin expansion through most of the fiscal year, with profitability levels stabilizing in the most recent quarter. This has translated into meaningful operating leverage, with adjusted EBITDA rising 35% year over year to about C$45 million for the nine months ended December 2025.

Aurora Cannabis’ latest updates further reinforce this trajectory. Management continues to prioritize international medical markets, where regulatory frameworks, pricing stability and demand visibility are more favorable compared to the recreational segment. The company is actively aligning its operations and capital allocation toward these markets, while streamlining lower-return activities to enhance overall profitability.

Aurora Cannabis expects global medical cannabis to remain its primary growth engine. The company expects fiscal 2026 medical cannabis revenues to be in the range of C$269-C$281 million, representing 10-15% year-over-year growth, supported by continued international expansion, new product launches and scaling in key European markets. Adjusted EBITDA is expected to reach C$52-C$57 million, with the company maintaining positive free cash flow as efficiencies improve.

ACB’s Consumer Cannabis Takes a Back SeatAurora Cannabis’ consumer cannabis business continues to weaken, reflecting structural challenges in Canada’s oversupplied adult-use market. Persistent price compression and aggressive competition have eroded both revenue potential and margins, making the segment increasingly unattractive relative to the company’s medical operations.

As a result, Aurora is now actively repositioning away from this segment. The company is scaling back participation in lower-margin consumer markets in Canada and redirecting capital and operational focus toward its higher-margin global medical cannabis platform. This shift highlights ACB’s effort to prioritize segments with stronger pricing power, more predictable demand and better long-term returns.

The strategic pullback is also expected to streamline Aurora’s cost structure. Management has indicated that reducing exposure to consumer cannabis should lower sales and marketing expenses and support consolidated margin expansion over time. However, the transition is not without near-term friction, with one-time costs expected to impact cash flow in the fourth quarter of fiscal 2026.

Intensifying CompetitionAurora Cannabis operates in an increasingly competitive global cannabis market, facing established players, such as Curaleaf Holdings  and Tilray Brands (TLRY - Free Report) . With most Canadian and international cannabis producers targeting a limited set of high-growth markets, competitive intensity remains elevated and could constrain ACB’s ability to sustain outsized market share gains.

This pressure is particularly pronounced in international markets, such as Europe, where Aurora Cannabis is focusing on its expansion strategy. Peers like Curaleaf and Tilray are also scaling their presence in these regions, increasing competition in the very markets expected to drive the company’s future growth. As a result, while international expansion offers meaningful opportunities, it also introduces execution risk and may limit pricing power over time.

ACB Valuation EstimatesEstimate movements for fiscal 2026 and 2027 have remained unchanged over the past 60 days.

Image Source: Zacks Investment Research

How to Play ACB Stock?Aurora Cannabis has made meaningful progress in repositioning its business, with medical cannabis emerging as a key growth driver and profitability improving. The company’s expanding footprint in international markets provides a pathway to offset structural challenges in Canada’s mature recreational market.

However, the investment case remains balanced. Persistent pricing pressure, ongoing weakness in the consumer cannabis segment and restructuring-related costs continue to weigh on near-term visibility. At the same time, rising competition in international markets could limit Aurora’s ability to fully capitalize on its medical cannabis momentum. Consistent earnings estimates suggest that the recent strategic progress is not yet translating into upward revisions, indicating limited near-term upside potential.

ACB currently carries a Zacks Rank #3 (Hold), which suggests that investors may be better off waiting for clearer signs of sustained earnings growth or improved industry conditions before building meaningful positions.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© PixelCatchers / E+ via Getty Images

Markets don’t usually wait for permission — they anticipate it. That’s why cannabis stocks jumped ahead of the official news that the Justice Dept. would reclassify marijuana from Schedule I to Schedule III. But here’s the real question investors should be asking: does this long-awaited shift actually change the investment case, or just the headlines?

Let’s dig into what this move means — and what it doesn’t.

A Long-Awaited Shift — and a Quick Reality Check The DOJ officially moved marijuana to Schedule III, placing it alongside drugs like ketamine and certain steroids instead of heroin or LSD. That’s not legalization — but it’s a meaningful policy shift.

The market reaction came fast:

Tilray Brands (NASDAQ:TLRY) rose 14% yessterday Canopy Growth (NASDAQ:CGC) climbed 21%  Aurora Cannabis (NASDAQ:ACB) was up a more muted 6.7% All three stocks are lower in midday trading, down mid- to high-single-digits That pullback tells you something important: traders were positioned early and are now taking profits. Step back further, and the longer-term picture looks less encouraging:

Company

Decline from  52-Week High

Tilray

-67%

Canopy Growth

-46%

Aurora Cannabis

-48%

That’s not a sector riding a wave of sustained momentum. It’s one still trying to find its footing.

What Schedule III Actually Changes Let’s strip away the jargon. Reclassification doesn’t legalize marijuana federally — states still operate under a patchwork of laws. But it does remove one major obstacle: IRS Code Section 280E. That means cannabis companies could now deduct ordinary business expenses.

Here’s why that matters:

Under Schedule I, companies couldn’t deduct payroll, rent, or marketing Effective tax rates often exceeded 60% to 70%, based on company filings and IRS guidance Moving to Schedule III allows normal corporate tax treatment — typically 21% federally That’s a direct hit to the bottom line — and a positive one.It also improves access to banking services (fewer restrictions for lenders), credit markets (lower borrowing costs), and Institutional capital (previously sidelined investors may step in)

Tilray, for example, reported in its latest earnings release that it generated $188 million in quarterly revenue, but profitability has remained inconsistent. Lower taxes could help — but only if core operations improve.

Canopy Growth, meanwhile, reported $78.5 million Canadian ($53.5 million) in quarterly revenue in its most recent filing, with continued net losses. Tax relief helps — but it doesn’t fix declining sales.

Reclassification vs. Legalization Is Still a Big Gap  Here’s where expectations and reality diverge. Investors have been waiting years for a breakthrough moment. This feels like one — but it’s not the finish line. Surprisingly, state-level legalization hasn’t delivered the growth many expected:

California’s legal cannabis market saw sales decline 11% year over year in 2025, its third consecutive year of decline Price compression from oversupply continues to pressure margins across multiple states Canada offers another cautionary tale. After full federal legalization in 2018, Canopy Growth and peers faced regulatory bottlenecks and high excise taxes, many producers struggled with inventory write-downs and excess capacity, while profitability has remained elusive years later. In other words, legalization didn’t eliminate business challenges — it exposed them.

Reclassification is an even smaller step.It removes friction, but doesn’t create demand.

Key Takeaway In short, this is progress. Real progress. Lower taxes, better banking access, and reduced stigma all help the industry mature.

But investing isn’t about headlines — it’s about outcomes. Here’s what the numbers and trends tell us:

Cannabis companies still struggle with profitability and pricing pressure Revenue growth has flattened or declined in key markets Stocks like Tilray Brands, Canopy Growth, and Aurora Cannabis remain far below their highs — 67%, 46%, and 48%, respectively Granted, lower taxes could improve margins. That said, margins only matter if there’s sustainable demand and disciplined supply. Reclassification is a necessary step. It is not a sufficient one. For investors, that distinction matters.

When all is said and done, cannabis remains a story of potential — not proven performance. Until these companies show consistent revenue growth, positive free cash flow, and pricing power, sharp investors should treat rallies like this as trading opportunities, not long-term entry points.

    NASDAQ | TSX: ACB

Q1 launches reinforce Aurora's medical‑first strategy, expanding access to high‑quality products across multiple formats Scaled launches across Canada, Europe and Australia support growing demand in regulated international medical markets Continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network , /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, is significantly expanding its global medical cannabis portfolio, with new product launches rolling out across Canada, Europe and Australia. The company continues to shape the global cannabis landscape by introducing new products and formats around the world. The newly expanded lineup includes dried flower, pre‑rolls and pastilles, reflecting Aurora's long‑standing focus on innovation, quality and patient choice, while driving sustainable growth internationally.

Aurora's global medical cannabis portfolio expansion. (CNW Group/Aurora Cannabis Inc.) "As our global medical business continues to grow, our focus remains on delivering consistency and reliability across the markets we serve," says Lana Culley, VP Innovation & International Operations at Aurora. "By expanding our offerings in key countries, we're responding to clear patient and prescriber demand with products that meet local regulatory standards, offer meaningful choice across formats, and can be supplied reliably at scale - all while reinforcing the level of quality and trust expected from us."

The new products align with Aurora's medical‑first strategy and leverage the company's global GMP‑certified manufacturing network.

Aurora's expanded medical cannabis offerings will roll out in their respective markets between now and June; new product launches include:

Germany – A broader portfolio of medical cannabis options

San Raf® – Pink OG KushTM | Indica, Dried Flower, THC 25-27%, CBD <1.0%. This cultivar has a spicy and sweet aroma profile of lemon, lavender, spice and is bred from OG Kush Daily SpecialTM – Lemon SorbetTM | Sativa, Dried Flower, THC 21%, CBD <1.0%. This cultivar has an aroma profile of spice, wood, lemon and is bred from Gelonade X Biscotti Poland – Expanded potency range across existing offerings

Cannabis flos Aurora - Electric HoneydewTM | Hybrid, Dried Flower, THC 27%, CBD ≤1.0%. This cultivar has an aroma profile of melon, gas, pine and is bred from Girl Scout Cookies x 91 OG Krypt Melon Cannabis flos Aurora – ChemangoTM Kush | Indica, Dried Flower, THC 29%, CBD ≤1.0%. This cultivar has an aroma profile of fruity, sour, chem and is bred from OG Kush x Wedding Cake x GMO x Fuel Australia – Featuring pastilles, an edible format that is discreet, precisely dosed, and long-lasting

Aurora® – Black Raspberry Pastilles | 60pck, THC 20mg, CBD 20mg, CBN 30mg Aurora® – Blood Orange Pastilles | 60pck, THC 32mg, CBD 32mg, CBG 32mg, CBC 10mg Canada - Medical portfolio growth in core formats

WMMCTM - Seasonal StashTM Dank MatterTM | Sativa, Dried Flower, 28g, THC 24-30%. This cultivar has an aroma profile of gas, licorice, vanilla, and is bred from Banana Puddintain x White Mac WMMCTM - Seasonal StashTM Custard KushTM | Indica, Dried Flower, 28g, THC 25-31%. This cultivar has an aroma profile of creamy, berry, oak, and is bred from La Bomba x White Mac San Raf® – Melon MouthTM | Hybrid, Pre-roll, 7x0.5g, THC 22-28%. This cultivar has an aroma profile of fruity, sweet, diesel and is bred from Girl Scout Cookies x Chem 91 x Crypt OG San Raf® – Stink BiscuitTM | Indica, Dried Flower, 3.5g, THC 22-28%. This cultivar has an aroma profile of gas, funk, sourdough and is bred from GMO x Animal Cookies Together, these launches reflect Aurora's continued role in advancing regulated medical cannabis globally, supporting the growth of these markets with high‑quality products, diverse formats, and reliable supply.

About Aurora 

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach. Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.

Learn more at www.auroramj.com and follow us on X and LinkedIn. 

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". 

Forward Looking Information 

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding new product launches across Aurora's key international markets, expectations for growing medical demand in regulated international markets, and the Company's continued focus on quality, patient needs and reliable global supply through Aurora's extensive GMP‑certified network.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, current and expected market trends, product supply and demand, financial performance, and ongoing global regulatory developments, as well as publicly available information from governmental sources, market research and industry, and assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

SOURCE Aurora Cannabis Inc.

NASDAQ | TSX: ACB

, /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2026 on Thursday, June 11, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter and fiscal year 2026 before the opening of markets that same day.

Conference Call Details

Aurora Cannabis to host fourth quarter and fiscal year 2026 investor conference call DATE:

Thursday, June 11, 2026

TIME:

8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time

WEBCAST:

Click Here

Miguel Martin, Executive Chairman and Chief Executive Officer, and Simona King, Chief Financial Officer, will host the conference call and question and answer period. This weblink has also been posted to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".

About Aurora Cannabis

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™. 

Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the timing for the release of the Company's fourth quarter and fiscal year 2026 financial statements and the conference call to discuss the results.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

SOURCE Aurora Cannabis Inc.

NASDAQ | TSX: ACB

Achieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growth Delivers Record Annual Adjusted EBITDA1 of $53.8 million, representing 32% YoY growth Completes Accretive Acquisition of Safari Flower Company in April, an established EU-GMP Manufacturer, adding Critical Capacity to Serve Growing Profitable International Markets Maintains Strong Balance Sheet with ~$164.7 million of Cash, Short Term Investments and Cash Equivalents2 with no Debt , /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2026 periods ending March 31, 2026.

FY26 Q4 EARNINGS RESULTS "During fiscal year 2026, we exceeded our projection for global medical cannabis net revenue1 led by double-digit growth in Europe and delivered on our expectation for Adjusted EBITDA1  with both at record outcomes. Our performance validates Aurora's global medical cannabis strategy which has positioned us as a leading provider in Canada, Europe, Australia, and New Zealand," said Executive Chairman and Chief Executive Officer for Aurora, Miguel Martin.

"We believe Aurora's leadership in medical cannabis is built upon our regulatory expertise, extensive and recently expanded supply network of EU-GMP certified facilities, and proven commercial execution. We are confident that these attributes create a competitive advantage as we navigate the evolving industry dynamics to maintain and expand global market share, while driving international growth," concluded Mr. Martin.

[1] This news release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. See "Non-GAAP Measures" below for reconciliations of non-GAAP financial measures to GAAP financial measures.

[2] Cash Equivalents refers to cash, restricted cash and cash equivalents.

Fourth Quarter 2026 Highlights

(Unless otherwise stated, comparisons are made between fiscal Q4 2026 and Q4 2025 results and are in Canadian dollars and reflects only the results of continuing operations, unless otherwise noted.

On February 17, 2026, the Company completed the divestiture of its 50.1% ownership interest in Bevo Agtech Inc. ("Bevo"). As such, Bevo has been excluded from the Company's Q4 2026 continuing results, along with comparative figures, due to its classification as a discontinued operation.)

Consolidated Revenue and Adjusted Gross Profit:    
Total net revenue1 was $84.8 million, as compared to $76.8 million in the prior year period. The 10% increase from the prior year period was mainly due to 14% growth in our global medical cannabis business and higher wholesale bulk cannabis net revenue, offset by lower quarterly net revenue1 in our consumer cannabis business.

Consolidated adjusted gross margin before fair value adjustments1 was 60% in Q4 2026 and 65% in the prior year period. Adjusted gross profit before FV adjustments1 was $50.5 million in Q4 2026 compared to $50.2 million in the prior year period.

Medical Cannabis:
Medical cannabis net revenue1 was $77.1 million, a 14% increase from the prior year period, delivering 91% of Aurora's Q4 2026 consolidated net revenue1 and 101% of adjusted gross profit before fair value adjustments1.

The increase in medical cannabis net revenue1 of $9.3 million was primarily due to higher sales in Germany, related to increased market size, and growth in Poland, along with higher revenue in Canada to insured patients related to broader portfolio offerings.

Adjusted gross margin before fair value adjustments1 on medical cannabis net revenue1 was 66% for the three months ended March 31, 2026, compared to 71% in the prior year period. The year-over-year decrease was due to higher sales with lower margins and strategic price reductions.

Consumer Cannabis:
Aurora's consumer cannabis net revenue1 was $3.6 million, compared to $8.2 million in the prior year period. The decrease was due to our strategic shift to focus on Canadian and international medical cannabis and wind down our consumer business.

Adjusted gross margin before fair value adjustments1 on consumer cannabis net revenue1 was 22%, a decrease from 27% compared to the prior year period. The decrease is primarily due to higher input costs related to third-party sourcing.

Adjusted Selling, General and Administrative ("Adjusted SG&A"):
Adjusted SG&A1 was $40.3 million for the three months ended March 31, 2026, compared to $35.4 million in the prior year period. The increase compared to the prior year period relates to increased headcount, higher contract labour in Europe and Australia, an expected credit loss of $1.9 million due to the insolvency of two customers and additional professional fees relating to public company costs incurred in the fourth quarter of the fiscal year.

Net Income (Loss):
Net loss from continuing operations for the three months ended March 31, 2026 was $27.6 million compared to a net loss of $12.1 million for the prior year period. The increase in net loss from continuing operations of  $15.4 million was primarily related to other expenses of $1.7 million in the current period, compared to other income of $11.9 million in the prior year period. This was slightly offset by an increase in gross profit of $2.5 million.

Adjusted Net Income:
Adjusted net income1 was $5.6 million for the three months ended March 31, 2026 compared to $15.3 million for the prior year period. The $9.7 million decrease primarily relates to an increase in adjusted SG&A of $4.9 million, a decrease in foreign exchange gains and interest income, of $10.3 million and $4.5 million, respectively.

Adjusted EBITDA:
Adjusted EBITDA1 was $9.2 million for the three months ended March 31, 2026 compared to $14.1 million for the prior year period.

Free Cash Flow:
Free cash flow was $0.3 million compared to $5.2 million in the prior year quarter. Free cash flow decreased by $4.9 million primarily due to a decrease in gross profit before fair value adjustments of  $5.3 million.

Strategic Business Update

Plant Propagation:
On February 3, 2026, Aurora and its wholly owned subsidiary entered into a definitive agreement with Bevo Agtech Inc and Bevo Farms Ltd. pursuant to which, among other things, Aurora agreed to exchange all of its common shares of Bevo for preferred shares of Bevo. On February 17, 2026, the transaction closed, resulting in the disposal of the Company's 50.1% ownership interest in Bevo and loss of control. The financial results of Bevo are no longer consolidated in Aurora's financial statements subsequent to the closing of the transaction. 

Safari Flower Company Acquisition:
On April 15, 2026, the Company acquired Safari Flower Company ("Safari"), through a share purchase acquisition, for total consideration of $26.5 million, subject to customary closing adjustments. The consideration is composed of $15 million in cash and 2,417,180 Common Shares with an approximate fair value of $11.5 million. Included in the total consideration is contingent consideration totaling $2 million upon satisfying certain GMP certifications.

The acquisition of Safari provides the Company with a 59,000 square foot EU-GMP certified indoor cultivation and manufacturing facility to supply cannabis to key international markets while reducing reliance on third party purchases.

Fiscal Full Year 2027 Outlook:
Our outlook reflects the strategic changes we have made in exiting our low margin Canadian Consumer and Plant Propagation businesses, which will allow the Company to reallocate resources to focus on global medical cannabis. We believe this is our highest return opportunity to create value.

Over the next few quarters, we are purposely investing in our international business through strategic sales initiatives and EU GMP capacity expansion to support growth in our most profitable markets. These efforts are expected to help offset the impact of margin reductions in our Canadian medical business, following the reduction in government reimbursed pricing, effective April 1, 2026.

Total Net Revenue1 is expected to decline and be more in line with our Cannabis Net Revenue results in fiscal year 2025, following the changes in Canadian medical partially offset by international growth, driven by Germany and Poland. Adjusted Gross Margin before FV adjustments1 are expected to be in the mid to high fifties, driven by higher revenue contributions from Europe and the exit from the lower margin businesses. These benefits will partially offset lower margins in Canadian Medical. Adjusted SG&A1 is expected to remain broadly in line with the prior fiscal year. Adjusted EBITDA1 is expected to vary quarter over quarter, leading to lower annual adjusted EBITDA1 compared to the prior fiscal year. This change in expectations is due to the revisions in reimbursed pricing that drive lower net revenue and adjusted gross profits contributions. Key Quarterly Financial Results

($ thousands)

Three months ended

March 31, 2026

December 31, 2025

$ Change

% Change

March 31, 2025

$ Change

% Change

Financial Results(3)

Net revenue (1)

84,816

82,893

1,923

2 %

76,768

8,048

10 %

Medical cannabis net revenue (1)

77,096

76,247

849

1 %

67,776

9,320

14 %

Consumer cannabis net revenue (1)

3,645

5,160

(1,515)

(29 %)

8,166

(4,521)

(55 %)

Adjusted gross margin before FV adjustments on
     total cannabis net revenue(1)

60 %

66 %

N/A

(6 %)

65 %

N/A

(5 %)

Adjusted gross margin before FV adjustments on medical
     cannabis net revenue(1)

66 %

69 %

N/A

(3 %)

71 %

N/A

(5 %)

Adjusted gross margin before FV adjustments on
     consumer cannabis net revenue(1)

22 %

28 %

N/A

(6 %)

27 %

N/A

(5 %)

Adjusted SG&A expense(1)

40,254

34,867

5,387

15 %

35,403

4,851

14 %

Adjusted EBITDA (1)

9,227

18,371

(9,144)

(50 %)

14,056

(4,829)

(34 %)

Adjusted net income (1)

5,581

11,711

(6,130)

(52 %)

15,272

(9,691)

(63 %)

Free cash flow (1)

316

18,569

(18,253)

(98 %)

5,249

(4,933)

(94 %)

Balance Sheet

Working capital (1)

330,523

299,901

30,622

10 %

367,465

(36,942)

(10 %)

Cannabis inventory and biological assets (2)

169,629

191,064

(21,435)

(11 %)

193,980

(24,351)

(13 %)

Total assets

601,087

775,292

(174,205)

(22 %)

852,666

(251,579)

(30 %)

(1)

These terms are defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.

(2)

Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies and consumables.

(3)

Results shown are from continuing operations. On February 17, 2026, the Company completed the divestiture of its 50.1% ownership interest in Bevo. As such, Bevo has been excluded from the Company's Q4 2026 continuing results, along with comparative figures, due to its classification as a discontinued operation.

Conference Call

Aurora will host a conference call today, Thursday, June 11, 2026, to discuss these results. Miguel Martin, Chief Executive Officer, and Simona King, Chief Financial Officer, will host the call starting at 8:00 a.m. Eastern time | 6:00 a.m. Mountain Time. A question and answer session will follow management's presentation.

DATE:

Thursday, June 11, 2026

TIME:

8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time

WEBCAST:

Click Here

About Aurora Cannabis

 Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™. 

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's fiscal 2026 results; statements under the heading "Fiscal Full Year 2027 Outlook ", including, but not limited to, those related to expectations for net revenue, adjusted gross margin before FV adjustments, adjusted EBITDA, and adjusted SG&A; statements regarding the Company's long-term outlook, ability to respond to changing global market dynamics and ability to mitigate the impact of margin reductions in the Canadian medical business; statements regarding the Company's global medical cannabis leadership and anticipated growth in the Company's international medical business; and statements regarding the Company's conference call to discuss results.

These forward-looking statements are only predictions. Forward-looking information or statements contained in this news release have been developed based on the Company and its management's good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company's business and operations in the future. Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things,  assumptions about: development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company's operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company's operations; and the Company's ability to conduct operations in a safe, efficient, and effective manner. The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company's business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond the Company's control. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crisis ,and other risks as set out under the heading "Risk Factors" in the Company's annual information form dated June 11, 2026 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com  and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Non-GAAP Measures

This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the FY26 Q4 MD&A is incorporated by reference into this news release. The MD&A is available on the Company's issuer profiles on SEDAR+ at www.sedarplus.com and on the U.S. Securities and Exchange Commission's (the "SEC") EDGAR website at www.sec.gov.

Net Revenue, Adjusted Gross Profit and Margin

Net revenue, adjusted gross profit before FV adjustments, and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with revenue, gross profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows:

($ thousands)

Three months ended

Years ended

March 31, 2026

December 31, 2025

March 31, 2025

March 31, 2026

March 31, 2025

Medical cannabis net revenue(1)

Canadian medical cannabis net revenue

28,314

28,250

26,751

112,116

107,432

International medical cannabis net revenue

48,782

47,997

41,025

176,524

137,010

Total medical cannabis net revenue(1)

77,096

76,247

67,776

288,640

244,442

Consumer cannabis net revenue(1)

3,645

5,160

8,166

23,548

40,033

Wholesale bulk cannabis net revenue(1)

4,075

1,486

826

8,405

4,436

Total net revenue(1)

84,816

82,893

76,768

320,593

288,911

(1)

These terms are defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.

Adjusted EBITDA

The following is the Company's adjusted EBITDA:

($ thousands)

Three months ended

Years ended

March 31, 2026

December 31, 2025(3)

March 31, 2025(3)

March 31, 2026

March 31, 2025(3)

Net income (loss) from continuing operations

(27,566)

6,317

(12,128)

(58,619)

27,050

Income tax expense (recovery)

(538)

97

3,285

2,095

4,245

Other expense (income)

1,673

2,322

(11,925)

9,862

(20,861)

Share-based compensation

689

(551)

3,786

7,293

12,930

Depreciation and amortization

3,871

4,583

3,379

16,228

15,430

Business development costs

850

443

624

1,975

3,435

Inventory and biological assets fair value and
impairment adjustments

20,487

1,306

21,953

50,419

(20,969)

Business transformation costs (1)

9,761

3,854

5,082

24,555

19,610

Adjusted EBITDA (2)

9,227

18,371

14,056

53,808

40,870

(1)

Business transformation related charges include costs related to closed facilities, certain IT project costs, sublease income, severance and retention costs in connection with the exit of the consumer market, legal provisions and costs associated with the retention of certain medical aggregators. 

(2)

Adjusted EBITDA is defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.

(3)

Prior period comparatives were adjusted to include the adjustments for markets under development, business transformation costs and non-recurring charges related to non-core bulk cannabis wholesale to be comparable to the current period presentation.

Adjusted Net Income

The following is the Company's adjusted net income (loss):

($ thousands)

Three months ended

Years ended

March 31, 2026

December 31, 2025

March 31, 2025

March 31, 2026

March 31, 2025

Net income (loss) from continuing operations

(27,566)

6,317

(12,128)

(58,619)

27,050

Inventory and biological assets fair value and
impairment adjustments

20,487

1,306

21,953

50,419

(20,969)

Business development costs

850

443

624

1,975

3,435

Impairment of property, plant and equipment

2,246

4

—

2,775

(696)

Impairment of intangible assets and goodwill

—

—

—

13,186

—

Deferred tax expense - impairment of intangible
assets and goodwill

—

—

—

5,856

—

Business transformation costs (1)

9,564

3,641

4,823

23,746

18,401

Adjusted net income (2)

5,581

11,711

15,272

39,338

27,221

(1)

Business transformation costs  include certain IT project costs, severance and retention costs in connection with the exit of the consumer market, legal provision and costs associated with the retention of certain medical aggregators.

(2)

Adjusted net income is defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures

Adjusted SG&A

Adjusted SG&A is a Non-GAAP Measure and can be reconciled with sales and marketing and general and administrative expenses, the most directly comparable GAAP financial measure, as follows:

Three months ended

Years ended

($ thousands)

March 31, 2026

December 31, 2025

March 31, 2025

March 31, 2026

March 31, 2025

General and administration

29,540

23,861

25,078

106,567

91,323

Sales and marketing

16,022

14,860

15,407

59,641

56,170

Business transformation costs (2)

(5,308)

(3,854)

(5,082)

(20,105)

(19,610)

Adjusted SG&A (1)

40,254

34,867

35,403

146,103

127,883

(1)

Adjusted SG&A is defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.

(2)

Business transformation costs include certain IT project costs, severance and retention costs in connection with the business transformation plan and costs associated with the consumer channel exit

Free Cash Flow

The table below outlines free cash flow for the periods ended:

Three months ended

Years ended

($ thousands)

March 31, 2026

December 31, 2025

March 31, 2025

March 31, 2026

March 31, 2025

Cash provided by (used in) operating activities
from continuing operations before changes in
non-cash working capital

(9,410)

9,517

(2,969)

1,386

4,764

Changes in non-cash working capital

11,823

10,573

9,736

(9,214)

14,205

Net cash provided by (used in) operating
activities from continuing operations

2,413

20,090

6,767

(7,828)

18,969

Less: maintenance capital expenditures(1)

(2,097)

(1,521)

(1,518)

(6,425)

(8,084)

Free cash flow(2)

316

18,569

5,249

(14,253)

10,885

(1)

Maintenance capital expenditures are comprised of costs to sustain facilities, machinery and equipment in working order to support operations and excludes discretionary investments for revenue growth.

(2)

Free cash flow is defined in the "Cautionary Statement Regarding Certain Non‑GAAP Performance Measures" section of the Annual MD&A, including information on reconciliation to the most directly comparable IFRS measures.

Working Capital

Working capital is a Non-GAAP Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable GAAP financial measure, as follows:

($ thousands)

Three months ended

March 31, 2026

December 31, 2025

March 31, 2025

Total current assets

397,453

445,836

488,548

Total current liabilities

(66,930)

(145,935)

(149,807)

Working capital

330,523

299,901

338,741

SOURCE Aurora Cannabis Inc.

Aurora Cannabis reported Q4/FY2026 results largely in line with expectations previously outlined by management. In recent months, the company has made the strategic decision to exit its lower margin consumer cannabis and plant propagation operations and focus on the growing European medical cannabis market. However, FY2027 will be impacted by adverse regulatory changes in the Canadian medical cannabis market. As a result, sales and margins are expected to decline quite meaningfully this year.

After years of restructuring, dilution, asset sales, and losses, investors remain sharply divided on whether Canopy Growth Corporation (CGC 0.49%) is finally stabilizing or simply extending a long decline.

Indeed, the next 12 months will likely provide an answer to that question.

Here are three realistic scenarios for where Canopy Growth stock could go next.

Image source: Getty Images.

Scenario 1: Canopy finally stabilizes This is the bullish case. Canopy has spent the past several years cutting costs, restructuring operations, and narrowing losses. In fiscal Q3 2026 (ended Dec. 31), the company reported revenue of $75 million Canadian dollars ($55 million) while adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) losses narrowed to about CA$3 million, marking its third consecutive quarter of improvement.

This isn't trivial because profitability has always been the central issue surrounding Canopy Growth.

The company also ended September 2025 with about CA$298 million in cash and cash equivalents, exceeding debt balances by roughly CA$70 million after making $50 million in debt prepayments.

Operationally, Canopy is finally showing pockets of growth again. Canada adult-use cannabis revenue increased 8% year over year in Q3, while medical cannabis revenue rose 15%. Management now believes the company can achieve positive adjusted EBITDA during fiscal 2027.

If Canopy can sustain revenue growth while maintaining cost discipline, investors may begin treating the company less like a distressed cannabis operator and more like a turnaround story.

Of course, that would require continued margin improvement, stable Canadian cannabis pricing, and stronger cash flow trends.

Under that scenario, the stock could recover meaningfully from current depressed levels.

Scenario 2: The company survives, but the stock goes nowhere This may be the most realistic outcome. Despite operational improvements, Canopy still faces structural problems that haven't disappeared.

The Canadian cannabis market remains oversupplied and intensely competitive. Pricing pressure continues to hurt margins across the industry, while regulatory delays limit meaningful U.S. expansion opportunities.

Meanwhile, Wall Street analysts still expect Canopy Growth to remain unprofitable for the foreseeable future, with some forecasts projecting only modest or little changed revenue growth over the next fiscal year.

That creates a difficult setup for shareholders. Canopy may ultimately survive financially without necessarily generating the type of earnings growth needed to justify a sustained stock rally.

This scenario would likely involve periodic dilution, continued restructuring, slow revenue growth, and ongoing volatility tied to cannabis legalization developments.

In other words, the company survives, but shareholders are stuck with dead money.

Today's Change

(

-0.49

%) $

-0.01

Current Price

$

1.00

Scenario 3: Another major breakdown This is the bearish case. Canopy has already undergone multiple restructurings, but the company still operates in an industry with weak pricing power, limited profitability, and uncertain regulation.

If Canadian cannabis pricing deteriorates further or consumer demand weakens, Canopy could quickly find itself back under financial pressure despite recent balance-sheet improvements. The company has still reported significant losses in fiscal 2026, including a Q3 net loss of about CA$63 million.

The cannabis sector also remains heavily dependent on investor sentiment. If broader market conditions weaken or capital becomes more expensive again, speculative cannabis stocks, many of which are still in prominent marijuana exchange-traded funds (ETFs), could face another major sell-off similar to previous industry downturns.

There's also execution risk. Canopy continues betting heavily on product innovation, premium brands, medical cannabis expansion, and international markets. But international cannabis sales actually declined sharply during parts of fiscal 2026 because of European supply chain problems.

If those operational challenges persist while revenue growth stalls, the market could begin to question whether the turnaround is truly sustainable.

The bottom line is simple: Canopy Growth long ago stopped being the hypergrowth marijuana stock story. Today, it's a restructuring and survival story.

The company has improved its balance sheet, narrowed losses, and stabilized parts of its business. But profitability remains elusive, the cannabis industry is saturated, and investor confidence remains fragile.

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) expects to release its financial results for the quarter and fiscal year ended March 31, 2026 before financial markets open on June 15, 2026. The Company also announced it plans to file restated financial results for the fiscal years ended March 31, 2025 and March 31, 2024 and to certain of the interim periods therein (the “Refiling”), in conjunction with its filing of.

Canopy Growth Corporation (CGC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of this company have returned -13.2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The Zacks Medical - Products industry, to which Canopy Growth belongs, has lost 11.1% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Canopy Growth is expected to post a loss of $0.06 per share, indicating a change of +93.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of -$0.36 for the current fiscal year indicates a year-over-year change of +87.9%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $0.11 indicates a change of +69.4% from what Canopy Growth is expected to report a year ago. Over the past month, the estimate has remained unchanged.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Canopy Growth.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Canopy Growth, the consensus sales estimate for the current quarter of $53.26 million indicates a year-over-year change of +17.6%. For the current and next fiscal years, $210.58 million and $278.96 million estimates indicate +8.9% and +32.5% changes, respectively.

Last Reported Results and Surprise HistoryCanopy Growth reported revenues of $53.47 million in the last reported quarter, representing a year-over-year change of +0.1%. EPS of -$0.1 for the same period compares with -$0.76 a year ago.

Compared to the Zacks Consensus Estimate of $50.59 million, the reported revenues represent a surprise of +5.7%. The EPS surprise was -233.33%.

Over the last four quarters, Canopy Growth surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Canopy Growth is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Canopy Growth. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Key Takeaways Canopy Growth posted 8% adult-use sales growth and 15% medical cannabis revenue growth in Q3.CGC expects MTL Cannabis acquisition to improve margins and expand medical cannabis reach.Canopy Growth targets positive adjusted EBITDA in fiscal 2027 amid pricing and tariff headwinds. Canopy Growth Corporation (CGC - Free Report) is back in focus as marijuana reclassification efforts revive investor interest in cannabis stocks. While the regulatory shift has improved sentiment across the sector, investors are increasingly separating companies with improving fundamentals from those still struggling to establish a sustainable business model.

CGC has recently taken steps to strengthen its operations through cost cuts, balance-sheet improvements and the acquisition of MTL Cannabis. However, persistent margin pressure and execution risks continue to cloud the company’s long-term outlook.

Let’s take a closer look at the company’s fundamentals to determine whether the stock deserves a place in investors’ portfolios following the marijuana reclassification push.

CGC Strengthens Medical Cannabis Push Amid Turnaround EffortsCanopy Growth is increasingly leaning on its Canadian medical cannabis franchise and product innovation strategy as it works toward a sustainable turnaround. The company’s latest quarterly performance highlighted improving traction in core cannabis operations, supported by stronger patient demand and continued momentum in select adult-use categories.

During the third quarter of fiscal 2026 (year ending March 2026), Canadian adult-use cannabis sales increased 8% year over year, benefiting from demand for infused pre-rolls and vape products across brands like Tweed, Claybourne and 7ACRES. On the medical side, revenues advanced 15%, aided by growth in insured patient registrations, higher order volumes and ongoing improvements in fulfillment and service levels.

Canopy has also expanded its medical cannabis portfolio through its Spectrum Therapeutics division by launching new 30- and 90-pack softgels and additional dosing formats. This reflects the company’s broader effort to deepen patient engagement and strengthen recurring medical revenue streams.

Beyond organic growth, the recently completed MTL Cannabis acquisition could further strengthen Canopy’s position in medical cannabis while improving cultivation efficiency and product quality. Management expects the deal to support margin expansion, provide access to premium flower supply and enhance the company’s ability to serve international markets, particularly Europe.

The company is also working to stabilize its international cannabis operations after prior supply-chain disruptions affected European sales. Management noted that improving flower availability, expanding strain selection and ongoing EU GMP progress at its Smiths Falls facility are expected to support sequential improvement through fiscal 2027.

At the same time, challenges remain. Cannabis gross margins declined year over year due to a weaker international mix and pricing pressures, while Storz & Bickel continues to face macroeconomic and tariff-related headwinds despite recent product launches. Canopy also continues to navigate reimbursement-related uncertainty in the Canadian medical market.

Still, management remains focused on cost discipline and expects the company to achieve positive adjusted EBITDA at some point during fiscal 2027.

Cutthroat Competition in the Cannabis SpaceCanopy Growth competes in an overcrowded market against large operators like Aurora Cannabis (ACB - Free Report) and SNDL Inc. (SNDL - Free Report) . Like CGC, these companies maintain a sizable presence in the Canadian cannabis market.

Aurora has increasingly prioritized higher-margin international medical cannabis markets, particularly Europe, while SNDL continues to expand its vertically integrated cannabis and retail operations through acquisitions and broad product offerings. These strategies are intensifying competition across key growth categories, including medical cannabis, vapes and premium flower.

As cannabis operators continue to pursue profitability and international expansion, Canopy will likely need to sustain product innovation, improve margins and successfully integrate MTL Cannabis to strengthen its competitive positioning.

CGC Stock Performance and EstimatesYear to date, shares of Canopy Growth have lost 6% compared with the industry’s 23% decline.

Image Source: Zacks Investment Research

Bottom-line estimates for fiscal 2026 and 2027 have remained stable in the past 60 days.

Image Source: Zacks Investment Research

How to Play CGC Stock?While marijuana reclassification efforts have improved sentiment toward cannabis stocks, Canopy Growth Corporation continues to face profitability and execution challenges despite recent operational improvements.

Investors should note that marijuana reclassification is still evolving gradually rather than through a sweeping federal transformation. Even if reforms progress, several restrictions surrounding U.S. cannabis businesses are likely to remain in place.

We would also like to remind investors that Canopy Growth does not directly operate cannabis businesses in the United States due to federal restrictions and exchange-listing considerations. The company maintains strategic exposure to the market through Canopy USA, which holds interests in Acreage Holdings, Wana Brands and Jetty.

Although CGC is targeting positive adjusted EBITDA in fiscal 2027, persistent margin pressure, reimbursement uncertainty and intense competition remain key risks. Given these factors, investors may want to hold off on initiating or adding to positions until Canopy Growth reports its fiscal fourth-quarter results. A cautious approach toward this Zacks Rank #3 (Hold) stock remains warranted.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the latest trading session, Canopy Growth Corporation (CGC - Free Report) closed at $1.07, marking a +1.9% move from the previous day. This move outpaced the S&P 500's daily gain of 0.02%. Elsewhere, the Dow gained 0.36%, while the tech-heavy Nasdaq added 0.07%.

The company's stock has dropped by 8.7% in the past month, falling short of the Medical sector's gain of 2.02% and the S&P 500's gain of 5.12%.

The investment community will be paying close attention to the earnings performance of Canopy Growth Corporation in its upcoming release. The company is slated to reveal its earnings on June 15, 2026. The company's upcoming EPS is projected at -$0.06, signifying a 93.62% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $53.26 million, indicating a 17.56% upward movement from the same quarter last year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.36 per share and a revenue of $210.58 million, representing changes of +87.92% and +8.94%, respectively, from the prior year.

Investors should also pay attention to any latest changes in analyst estimates for Canopy Growth Corporation. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Currently, Canopy Growth Corporation is carrying a Zacks Rank of #3 (Hold).

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 160, putting it in the bottom 35% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes launched under Tweed brand

Up to five additional strains expected to follow in June 2026

Company targeting rapid growth in Germany’s medical cannabis market

SMITH FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced the relaunch of the Tweed brand in the German medical market, alongside the introduction of three cannabis strains developed by MTL Cannabis Corp. (“MTL”), a wholly-owned subsidiary of the Company. The dual milestone represents the Company’s first international product release following its recent acquisition of MTL.

The Tweed brand relaunch – now powered by MTL’s premium genetics – signals the Company’s commitment to leveraging the full equity of its legacy brand in key international markets and comes as Germany’s medical cannabis market continues to expand rapidly, approaching $1 billion in annual value in 20251. The MTL acquisition has enhanced Canopy Growth’s capacity to meet rising demand in key international markets, including Germany, while reintroducing a brand that physicians and patients have come to trust.

"Germany is one of the fastest-growing medical cannabis markets globally, and demand continues to scale rapidly. The relaunch of our Tweed brand is a meaningful moment for us, reflecting both the strength of what we have built, and our commitment to delivering consistent, high-quality cannabis that physicians can prescribe with confidence and patients can rely on as part of their care. We believe the European Union represents a tremendous opportunity for Canopy, and Germany is just the beginning,” said Luc Mongeau, Chief Executive Officer, Canopy Growth.

The initial launch includes three cultivars – Pablo’s Revenge, Dante’z Inferno, and Frost’d Flakes – selected for their quality and consistency. Up to five MTL-derived strains are expected to be introduced in June 2026, with further portfolio expansion planned throughout the year.

The Company also announced today that it has been granted a management cease trade order effective as of May 28, 2026, by its principal regulator, the Ontario Securities Commission under National Policy 12-203 – Management Cease Trade Orders. This follows the Company’s announcement on May 15, 2026 regarding certain non-cash technical errors in the Company’s accounting relating to certain share-settled warrants of the Company with exercise prices denominated in U.S. dollars, first issued during the fiscal year ended March 31, 2024. The Company intends to refile the relevant financial statements (the “Refiling”) in its Annual Report on Form 10-K for the fiscal year ended March 31, 2026, which is expected to be filed with Canadian securities regulators and with the United States Securities and Exchange Commission (the “SEC”) on June 15, 2026 (the “Comprehensive Form 10-K”).

About Canopy Growth

Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond.

Canopy Growth is Canada’s leading provider of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.

Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being.

For more information visit www.canopygrowth.com

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements with respect to the occurrence, timing and expectations relating to further portfolio expansion in European markets including an additional five MTL-derived strains expected to be introduced in 2026; the outstanding work and the planned filing of the Refiling; the expected timing of the filing of the Comprehensive Form 10-K; disclosure of further updates and bi-weekly status reports with respect to the MCTO; the timing, duration and impacts with respect to the MCTO; and expectations for other economic, business, and/or competitive factors.

Risks, uncertainties and other factors involved with forward-looking information or statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including delays in completing the Refiling and the Comprehensive Form 10-K; risks relating to the dilutive impact of the transactions and future resales of Common Shares in the public market, which may negatively affect the stock price of Common Shares; negative operating cash flow; uncertainty of additional financing; use of proceeds; volatility in the price of the Common Shares; risks relating to the overall macroeconomic environment, which may impact customer spending, costs and margins, including tariffs (and related retaliatory measures), the levels of inflation, and interest rates; expectations regarding future investment, growth and expansion of operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis; additional dilution; political risks and risks relating to regulatory change, including with respect to reimbursement rates in the medical cannabis market; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the SEC through EDGAR at www.sec.gov/edgar, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2025 and its subsequently filed quarterly reports on Form 10-Q.

In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information or statements and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

In the latest close session, Canopy Growth Corporation (CGC - Free Report) was down 1.85% at $1.06. The stock fell short of the S&P 500, which registered a gain of 0.13% for the day. Elsewhere, the Dow gained 0.45%, while the tech-heavy Nasdaq added 0.03%.

The company's stock has dropped by 1.82% in the past month, falling short of the Medical sector's gain of 1.01% and the S&P 500's gain of 5.25%.

The upcoming earnings release of Canopy Growth Corporation will be of great interest to investors. The company's earnings report is expected on June 15, 2026. The company is predicted to post an EPS of -$0.06, indicating a 93.62% growth compared to the equivalent quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $53.26 million, up 17.56% from the prior-year quarter.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.36 per share and a revenue of $210.58 million, representing changes of +87.92% and +8.94%, respectively, from the prior year.

Investors should also note any recent changes to analyst estimates for Canopy Growth Corporation. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Canopy Growth Corporation presently features a Zacks Rank of #3 (Hold).

The Medical - Products industry is part of the Medical sector. With its current Zacks Industry Rank of 153, this industry ranks in the bottom 38% of all industries, numbering over 250.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Canopy Growth Corporation (CGC - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this company have returned -9.6% over the past month versus the Zacks S&P 500 composite's +4.6% change. The Zacks Medical - Products industry, to which Canopy Growth belongs, has lost 4.3% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, Canopy Growth is expected to post a loss of $0.06 per share, indicating a change of +93.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

For the current fiscal year, the consensus earnings estimate of -$0.36 points to a change of +87.9% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $0.11 indicates a change of +69.4% from what Canopy Growth is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Canopy Growth is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Canopy Growth, the consensus sales estimate of $53.26 million for the current quarter points to a year-over-year change of +17.6%. The $210.58 million and $278.96 million estimates for the current and next fiscal years indicate changes of +8.9% and +32.5%, respectively.

Last Reported Results and Surprise HistoryCanopy Growth reported revenues of $53.47 million in the last reported quarter, representing a year-over-year change of +0.1%. EPS of -$0.1 for the same period compares with -$0.76 a year ago.

Compared to the Zacks Consensus Estimate of $50.59 million, the reported revenues represent a surprise of +5.7%. The EPS surprise was -233.33%.

Over the last four quarters, Canopy Growth surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Canopy Growth is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Canopy Growth. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) today announced that Claybourne’s Frosted Flyers Variety Pack has been awarded Best Infused Pre-Roll at the 2026 Grow Up Awards, presented during the annual Grow Up Conference & Expo in Toronto.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608930080/en/

Frosted Flyers Variety Pack

Building on that recognition, the Company also announced the expansion of Claybourne’s Frosted Flyers infused pre-roll lineup in Canada, with three new 8-pack variety formats and the brand’s first bundle pack.

“Winning Best Infused Pre-Roll at Grow Up is a clear signal that consumers and the industry are responding to what Claybourne is building in Canada,” said Luc Mongeau, Chief Executive Officer, Canopy Growth. “Frosted Flyers was designed to bring more flavour and energy to the infused pre-roll category, and this recognition tells us we’re delivering on that. Today’s expansion extends our market share momentum, giving consumers more ways to discover the brand and more reasons to reach for Claybourne this summer.”

The expanded Frosted Flyers infused pre-roll lineup includes:

Frosted Flyers Podium Pack | 8x0.35g | Eight flavours, eight pre-rolls, one variety pack Frosted Flyers Fast Pack | 8x0.35g | Four sativa flavours, eight pre-rolls, two of each flavour Frosted Flyers Drag Pack | 8x0.35g | Four indica flavours, eight pre-rolls, two of each flavour Frosted Flyers Variety Bundle Pack | 2x5x0.5g | Five flavours, 10 pre-rolls, one cost-effective bundle pack With the addition of the Podium Pack, Fast Pack, Drag Pack, and Variety Bundle Pack, Claybourne is extending its position in multi-pack formats while meeting growing consumer demand for variety and convenience – expanding at a key seasonal moment.

“‘Built on Variety’ started as a product idea and has since evolved into a core part of our product identity,” said Jonathan Griffith, Co-Founder and VP of Marketing at Claybourne Co. “Consumers want options, and they want products that fit different occasions. These new 8x0.35g Podium, Fast and Drag packs build on that momentum with quicker sessions, more flavour rotation and curated experiences designed around how people actually consume.”

Availability

The new Frosted Flyers variety packs are now rolling out at select retail stores across Canada, with all formats available this summer.

About Canopy Growth

Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Its portfolio of owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category defining Storz & Bickel, delivers innovative products to consumers across Canada and beyond.

Canopy Growth is one of Canada’s leading providers of medical cannabis services through Canada House Clinics and serves patients online via Abba Medix. The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.

Committed to quality, responsible use, and community, Canopy Growth is shaping a future where cannabis is embraced for its potential to enhance well-being.

For more information visit www.canopygrowth.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260608930080/en/

The cannabis industry has been a disappointment. Although Wall Street had high hopes for marijuana stocks toward the end of the last decade, as legal and regulatory progress in the market made pot growers more attractive, almost every one of them has significantly underperformed broader equities in recent years. Tilray Brands (TLRY 2.73%), a leader in the industry, has been no exception: The company's shares have declined by more than 90% over the past five years. However, some investors hope that recent developments in the U.S. cannabis market could be a turning point for Tilray. Is now a good time to bet on the stock?

Image source: The Motley Fool.

A gift from the government Following an executive order signed by President Trump, products approved by the U.S. Food and Drug Administration that contain marijuana -- as well as medical cannabis products that are legal in certain states -- have been moved from Schedule I to Schedule III. Here's what that means. Under federal law, Schedule I substances are deemed the most addictive while having no recognized medical benefits. Products in the Schedule III category are considered less prone to abuse. This change will make it easier to research potential health-related benefits of marijuana, something that could move the needle for pot growers that operate in the U.S. Tilray is ready to take on this opportunity through its footprints in the U.S. market, where it offers a variety of CBD and hemp-based products, as well as a craft-brewing business.

We have seen this movie before It's worth noting that the recent rescheduling decision does not include recreational marijuana. However, there is a hearing on the books for next month to discuss whether other forms of cannabis should also be rescheduled. Even assuming the best-case scenario for Tilray, though, it is less than clear that this will be the major turning point many investors hope for. Rescheduling cannabis wouldn't make the substance legal at the federal level. So, significant barriers would remain.

Today's Change

(

-2.73

%) $

-0.14

Current Price

$

4.98

For instance, it would still be illegal to ship the substance across state lines. This restriction forces many cannabis companies to own and operate facilities to cultivate and process cannabis -- as well as to make various products derived from the substance -- in every state where they do business, instead of relying on one or a few such sites spread out in several states that ship products to every other one. This is an incredibly inefficient way to do business that pot growers are forced into, leading to significantly higher operating expenses than they would otherwise incur.

That's one of the reasons most cannabis companies in the U.S. are unprofitable. True, rescheduling will help medical cannabis companies in the country by allowing them to deduct normal business expenses (companies selling Schedule I or Schedule II drugs aren't allowed to do that), thereby lowering operating costs. But there are other problems. Just like it dealt with significant competition in Canada once recreational uses of cannabis were legalized in the country in 2018, Tilray might encounter the same issue here.

Even with the company's large portfolio of products and brands, it isn't clear that it has developed a competitive advantage that would allow it to emerge as one of the winners. And that would be the case even if federal legalization happens in the U.S. That might certainly open massive opportunities, but it would also attract far larger corporations with the financial means, brand recognition, and expertise in navigating industries with tough regulatory landscapes.

In fairness to Tilray, it has significantly diversified its lineup in recent years. It is now the fourth-largest craft brewer in the U.S. thanks to a series of acquisitions. That said, the company continues to generate inconsistent revenue growth. It also remains unprofitable.

TLRY Revenue (Annual) data by YCharts

Given Tilray's track record, its poor financial results, and the industry's uncertainty, it's hard to make a solid case that the company's long-term outlook is attractive. Investors shouldn't bother with this stock, even though it is trading just slightly above penny-stock territory.

Tilray Brands NASDAQ:TLRY stock price has plummeted this year, and is now hovering at its lowest level since July last year. It has plunged by 76% from its highest point last year, meaning that a $10,000 investment at its peak would be about $2,100 today. 

Tilray Brands and other cannabis companies have come under intense pressure. While the cannabis industry is growing in key countries, the reality is that it has not become the vibrant sector that people were expecting after the famous Supreme Court ruling. 

Recent studies estimate that the US market size for cannabis stands at over $30 billion, with its compounded annual growth rate (CAGR) being 4.5%. In the past, estimates were that it would have double digit growth rates over time.

Tilray shares jumped to $9.30 in April after the US made efforts to reclassify cannabis into a less dangerous drug. This happened after the industry spent millions of dollars lobbying and financing Trump’s campaign.

The reclassification would benefit Tilray Brands as it has expressed a desire to enter the market. Still, the proces will take time, including a lawsuit brought by prohibitionist organization and drug-testing groups. These lawsuits are the ones that derailed Joe Biden’s reclassification efforts.

Meanwhile, the company’s entry into the beverage industry is not going on as planned. A look at its financial reports shows that its revenue and margins have remained under pressure in the past few months. 

The most recent results showed that its revenue dropped to $42.6 million in the last quarter from $56 million in the same period last year. Its gross margin also dropped to 32% from the previous 36%. It was the worst-performing division in its business in terms of revenue growth. 

The company has also continued to lose money in the past few years. Its loss improved to $25.2 million in the quarter compared to a $793 million in the same period a year earlier. Still, it will take longer for the company to achieve stable profits.

These fears explain why investors have continued to short the stock. Data shows that its short interest has jumped to 16.4%, higher than other companies in the industry. This rising short interest is putting more pressure on its business.

Analysts expect that Tilray’s revenue will continue to grow in the near term. The average estimate is that its annual revenue will jump by 7.6% this year to $884 million, followed by $1.1 billion next year.

TLRY stock chart | Source: TradingView

The daily chart shows that the TLRY share price has crashed in the past few months. After peaking at $9.30 in April, it has plunged to $5.45 today. It has moved below the important support level at $5.96, its lowest level in April, confirming the bearish outlook.

The stock has remained below the 50-day and 100-day Exponential Moving Averages (EMA). Remaining below these averages is a sign that bears have prevailed today.

Tilray remains below the Ichimoku Cloud and the Supertrend indicator. Therefore, the most likely scenario is where it continues falling, potentially to the psychological level at $5. A move below that level will point to more downside towards $4.5.

However, it is worth noting that Tilray and other cannabis companies are often highly volatile when major news come out. As such, there is also a possibility that it will have a short squeeze.

Top Canadian Cannabis Stocks to Watch Before June 2026 The Canadian cannabis sector continues showing signs of long-term potential heading into June 2026. Several companies are expanding globally while improving operational efficiency. In addition, many cannabis investors are watching for future developments in the United States’ reform. Those possible reforms could create new growth opportunities across the industry. However, volatility remains high in cannabis stocks. Because of this, traders should continue using technical analysis and proper risk management strategies. Strong balance sheets and improving revenue trends are becoming increasingly important for investors. Furthermore, companies with diversified operations may perform better during uncertain market conditions. Three Canadian cannabis companies continue attracting investor attention this month. These companies include TLRY, CGC, and VFF.

[Read More] Top Multi-State Marijuana Penny Stocks to Watch Right Now

3 Canadian Marijuana Stocks Investors Are Watching Heading Into June 2026 Tilray Brands Inc. (NASDAQ: TLRY) Canopy Growth Corporation (NASDAQ: CGC) Village Farms International Inc. (NASDAQ: VFF) Tilray Brands Inc. (TLRY) Tilray Brands remains one of the most recognized cannabis companies in Canada. The company operates across cannabis, beverage alcohol, and wellness markets. Additionally, Tilray maintains a large international presence throughout Europe and North America. Its strongest exposure in the United States comes through craft beer and beverage operations. Meanwhile, the company continues expanding medical cannabis distribution throughout Europe. Tilray does not currently operate U.S. THC dispensaries because federal legalization has not occurred. However, the company maintains strategic positioning for future American cannabis opportunities. Tilray’s Canadian operations include several cultivation and processing facilities across the country.

The company also owns multiple cannabis brands targeting different consumer categories. Furthermore, Tilray continues focusing on premium products and derivative cannabis items. Investors continue watching the company because of its international diversification strategy. Its broad operational structure provides exposure beyond traditional cannabis sales. In addition, Tilray continues to pursue partnerships and acquisitions to strengthen its market share. Many investors believe the company could benefit significantly from future federal reform in the United States. As a result, TLRY remains one of the most actively traded cannabis stocks entering June 2026.

Latest Financials Tilray recently reported quarterly financial results showing continued revenue diversification. Beverage alcohol sales remained an important contributor to the company’s overall performance. Meanwhile, cannabis revenue was under pressure from price competition across Canada. However, international medical cannabis sales continued showing gradual improvement. Gross margins also improved slightly compared to previous quarters. Additionally, management continued emphasizing cost reductions and operational efficiency initiatives. Tilray reported ongoing efforts to lower production expenses across several facilities. Cash preservation remains another important company objective during current market conditions.

Furthermore, management discussed future growth opportunities in Germany and other European markets. Tilray also continues to reduce debt while strengthening its financial flexibility. Although profitability challenges remain, investors continue to monitor operational progress carefully. Analysts remain focused on whether revenue growth can outpace industry pricing pressure. Still, Tilray’s diversified business model separates it from many cannabis competitors. The company’s beverage operations also provide additional revenue stability during cannabis market weakness. Consequently, many investors continue viewing TLRY as a long-term cannabis industry watchlist candidate.

[Read More] Cannabis REITs Gaining Momentum in 2026: 3 Stocks to Watch

Canopy Growth Corporation (CGC) Canopy Growth Corporation remains another major Canadian cannabis company that investors continue monitoring closely. The company operates recreational and medical cannabis businesses throughout Canada and international markets. Additionally, Canopy maintains strategic exposure to future United States cannabis opportunities. Its largest U.S. positioning comes through cannabis-related investment structures and partnerships. However, federal restrictions still prevent direct THC dispensary operations within the United States. Canopy currently does not operate American cannabis dispensaries. Nevertheless, investors continue to watch the company’s U.S. expansion potential closely.

The company owns several recognized cannabis brands across multiple product categories. These include dried flower, beverages, edibles, and vape products. Furthermore, Canopy continues to emphasize premium cannabis products and the development of the medical market. The company has also focused heavily on restructuring efforts during recent years. Management continues working to streamline operations and improve overall efficiency. In addition, Canopy remains one of the sector’s most widely recognized cannabis brands globally. Investors often view the company as a high-risk, high-reward cannabis opportunity. Strong market reactions frequently follow company updates and restructuring announcements. Therefore, CGC remains one of the most actively watched Canadian cannabis stocks before June 2026.

Latest Financials Canopy recently reported financial results reflecting ongoing restructuring progress and expense reductions. Revenue remained under pressure due to competitive conditions in the Canadian cannabis industry. However, management reported improvements in operational efficiency and cost controls. The company also reduced losses compared to prior reporting periods. Additionally, Canopy continued to focus on premium product categories with higher margins. International medical cannabis operations also provided some positive revenue contributions. Furthermore, management emphasized maintaining liquidity and strengthening the balance sheet.

Cost-cutting measures remained a central part of the company’s turnaround strategy. Investors also continue monitoring Canopy’s path toward sustainable profitability. Although challenges remain, management believes restructuring efforts are creating long-term stability. Canopy also continues evaluating strategic opportunities tied to future U.S. legalization developments. Analysts remain divided regarding the company’s long-term outlook. Nevertheless, many traders continue watching the stock because of its volatility and news sensitivity. Strong price swings often occur following cannabis reform headlines or earnings announcements. Consequently, CGC remains an important stock for cannabis investors to monitor closely before June 2026.

[Read More] 3 Marijuana Stocks For Better Investing In 2026

Village Farms International Inc. (VFF) Village Farms International operates a diversified agricultural and cannabis business model. The company originally built its reputation through greenhouse vegetable production. Later, Village Farms expanded aggressively into the cannabis industry. Today, the company operates cannabis cultivation facilities throughout Canada. Additionally, Village Farms owns the Pure Sunfarms cannabis brand. Pure Sunfarms remains one of Canada’s leading cannabis producers by volume. The company also maintains exposure to potential future opportunities in the United States cannabis market.

However, Village Farms currently does not operate U.S. THC dispensaries because of federal restrictions. Its strongest American presence comes through agricultural operations and CBD-related business activities. Furthermore, Village Farms continues to emphasize efficient, low-cost cannabis cultivation. This strategy has helped the company compete within Canada’s highly competitive cannabis market. Investors often view Village Farms as one of the sector’s more disciplined operators. Management also continues focusing on profitability and operational consistency. In addition, the company benefits from decades of expertise in large-scale greenhouse cultivation. As a result, VFF remains a closely watched cannabis stock entering June 2026.

Latest Financials Village Farms recently reported quarterly financial results showing continued operational improvement. Cannabis revenue remained supported by strong demand for Pure Sunfarms products across Canada. Additionally, management highlighted efforts to improve margins within the cannabis division. The company also continued emphasizing disciplined expense management and production efficiency. Gross profit improved compared to several prior reporting periods. Furthermore, Village Farms maintained a stronger balance sheet than many cannabis competitors. Management also discussed future expansion opportunities within international cannabis markets.

The company continues pursuing growth opportunities while avoiding excessive operational spending. Investors continue monitoring whether profitability trends can remain sustainable throughout 2026. Meanwhile, Village Farms benefits from diversified agricultural operations outside cannabis markets. This diversification may help reduce overall business volatility during difficult industry conditions. Analysts also continue monitoring the company’s ability to gain additional market share in Canada. Furthermore, many investors appreciate Village Farms’ focus on efficiency and disciplined execution. Although the risks in the cannabis sector remain elevated, VFF continues to attract investor attention. Consequently, the stock remains an important Canadian cannabis company to watch before June 2026.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]